Moderna’s stock price (MRNA) rose in the intraday levels, while tackling the pivotal resistance of $116.00, amid positive pressure from the 50-day SMA, and with the dominance of the upward correctional trend in the short term, with positive signals from the RSI after reaching oversold levels. 

Therefore we expect more gains for the stock, targeting the pivotal resistance of $116.00, provided the support of $99.30 holds on.

Trend forecast: Likely Bullish